Roivant Sciences
Immunovant Announces Pricing of $550 Million Common Stock Financing
Immunovant; IMVT; common stock offering; $550 million financing; equity financing; underwritten offering; IMVT-1402; Roivant Sciences; Leerink Partners; biotech capital raise
Delaware Judge Rules in Favor of Roivant Subsidiary Arbutus in COVID-19 Vaccine Patent Dispute with Moderna
Moderna, Arbutus Biopharma, Roivant Sciences, COVID-19 vaccine, Patent infringement, Judge Mitchell Goldberg, Lipid nanoparticles (LNP), Claim construction order